Payment overview · 2025
General Payments
$571.59
31 reported records · 13 companies
Healthcare provider profile · identity verified
Sidney Rivers Jones, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHMOND, VA · NPI 1316909112
Verified facts
What the public records show
CMS Open Payments records show Sidney Rivers Jones, MD received $571.59 in general payments during 2025 across 31 reported records.
PFIZER INC. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nexlizet by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.56 | 14.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.93 | 13.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.63 | 12.7% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $69.90 | 12.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.14 | 10.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.85 | 9.2% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $35.44 | 6.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.99 | 4.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.28 | 3.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 3.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $18.09 | 3.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.53 | 2.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.40 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.74 | 30 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $72.63 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.63 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $69.90 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.28 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $62.28 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.14 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.74 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.99 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 712 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 183 |
| Amlodipine Besylate | Amlodipine Besylate | 560 | 161 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 411 | 112 |
| Omeprazole | Omeprazole | 318 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 312 | 81 |
| Lisinopril | Lisinopril | 304 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 297 | 83 |
| Simvastatin | Simvastatin | 296 | 79 |
| Gabapentin | Gabapentin | 259 | 63 |
| Sertraline Hcl | Sertraline Hcl | 231 | 63 |
| Trazodone Hcl | Trazodone Hcl | 213 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 175 | 47 |
| Alprazolam | Alprazolam | 163 | 41 |
| Valsartan | Valsartan | 161 | 48 |
| Losartan Potassium | Losartan Potassium | 154 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 45 |
| Metformin Hcl | Metformin Hcl | 150 | 41 |
| Carvedilol | Carvedilol | 149 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 137 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 51 |
| Montelukast Sodium | Montelukast Sodium | 130 | 37 |
| Eliquis | Apixaban | 128 | 28 |
| Famotidine | Famotidine | 128 | 41 |
| Furosemide | Furosemide | 127 | 33 |
| Metformin Hcl Er | Metformin Hcl | 125 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 31 |
| Ezetimibe | Ezetimibe | 115 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 46 |
| Lorazepam | Lorazepam | 110 | 22 |
| Buspirone Hcl | Buspirone Hcl | 109 | 19 |
| Allopurinol | Allopurinol | 104 | 31 |
| Bupropion Xl | Bupropion Hcl | 104 | 23 |
| Synthroid | Levothyroxine Sodium | 104 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 23 |
| Jardiance | Empagliflozin | 99 | 21 |
| Meloxicam | Meloxicam | 93 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 25 |
| Irbesartan | Irbesartan | 82 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 23 |
| Mirtazapine | Mirtazapine | 72 | 22 |
| Potassium Chloride | Potassium Chloride | 70 | 18 |
| Tramadol Hcl | Tramadol Hcl | 66 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 25 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 61 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 11 |
| Glipizide Er | Glipizide | 58 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 19 |
| Finasteride | Finasteride | 52 | 13 |
| Spironolactone | Spironolactone | 51 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 11 |
| Atenolol | Atenolol | 49 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 15 |
| Chlorthalidone | Chlorthalidone | 45 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 12 |
| Prednisone | Prednisone | 45 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Diazepam | Diazepam | 43 | 12 |
| Benazepril Hcl | Benazepril Hcl | 42 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 42 | suppressed |
| Methocarbamol | Methocarbamol | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 39 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Pregabalin | Pregabalin | 40 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 15 |
| Nexlizet | Bempedoic Acid/Ezetimibe | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 15 |
| Estradiol | Estradiol | 30 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | 11 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 21 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Azithromycin | Azithromycin | 21 | 20 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Ritalin | Methylphenidate Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $571.59 · 31 records | PFIZER INC. | Cologuard Collection Kit, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, INSPIRE, JARDIANCE, MOUNJARO, NEXLETOL, NURTEC ODT, OPSUMIT, Ozempic, PROLIA, Rybelsus, UPTRAVI, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error